ETFs & MarketsPremiumAllogene Extends Cash Runway to 2029: What it Means for Biotech ETFs
Allogene Therapeutics has issued a strategic update regarding its capital reserves, projecting a cash runway that now extends into the first quarter of 2029. This announcement comes alongside a revision of its 2026 operating cash expense guidance, which has been raised to approximately $165 million.
Published 4 hours ago
Read more →